BEAM Alliance 10th AMR meeting 2026, Basel
11 March 2026Last week, CSO Mat Upton and CEO Gordon Barker travelled to Basel, Switzerland for the BEAM Alliance 10th AMR meeting.…
Last week, CSO Mat Upton and CEO Gordon Barker travelled to Basel, Switzerland for the BEAM Alliance 10th AMR meeting.…
On 14th December, CSO Mat Upton was invited to attend the Final Forum of the Saudi Biotechnology Accelerator (SBA) in…
Amprologix celebrates research excellence at the University of Plymouth as CSO Professor Mat Upton presents the Research Excellence Award to…
Amprologix has raised £740,000 to accelerate the development of our breakthrough antibiotic Epidermicin NI01. This investment also supports our AI-driven…
We are pleased to announce that Professor Mat Upton, Chief Scientific Officer at Amprologix, will represent the company at the…
Last week, CSO Mat Upton and CEO Gordon Barker travelled to Basel, Switzerland for the BEAM Alliance 10th AMR meeting. Read on for some of Mat’s thoughts on a productive and thought provoking trip… 10th AMR conference, Basel Gordon and I were back in Basel last week for the annual AMR meeting. These meetings always […]
Amprologix has raised £740,000 to accelerate the development of our breakthrough antibiotic Epidermicin NI01. This investment also supports our AI-driven antimicrobial discovery platform, reinforcing our mission to tackle global antimicrobial resistance by developing novel antimicrobials.
Amprologix joins a global network of innovators We're proud to announce that Amprologix is one of the 103 finalists selected to participate in the MassChallenge Switzerland & UK Accelerator Programme 2025, chosen from a pool of 1,527 high-potential startups worldwide. This milestone places Amprologix among a global community of science-driven innovators who are committed to […]
Amprologix files the first of a new series of patents protecting novel molecular structures for the treatment of bacterial infections. July 2024 Amprologix has filed its first patent in a series aimed at developing novel molecular structures for the treatment of bacterial infections. This significant milestone stems from discoveries made by Amprologix's proprietary AI “discovery […]
